News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

28th Apr 20

Pharmaxis Cancer Drug Ready to Commence Myelofibrosis Phase 2 Studies Q4 2020

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that following positive results from phase 1b and long term toxicity studies, the company is now progressing to a phase 2 study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF).

  • Multiple ascending dose stage of Phase 1 trial demonstrates a well-tolerated drug that effectively inhibits all enzymes in the lysyl oxidase family that are involved in fibrosis.
  • Long term toxicity studies completed clearing the way for 6-month phase 2 studies in several cancers with opportunity to demonstrate disease modifying efficacy.
  • Pre-clinical program, regulatory advice and opinion from leading clinicians supports progression into phase 2 study of myelofibrosis, a rare bone cancer with high unmet need and significant market opportunity.
  • Pharmaxis advances its clinical stage pipeline in fibrosis that includes selective LOXL2 inhibitors (PXS-5382 and PXS-5338) for chronic fibrotic diseases like NASH and IPF, the oral pan-LOX inhibitor (PXS-5505) for acute fibrosis and cancer, and a topical pan-LOX inhibitor for scarring.
Read full media release - pdf
18th Dec 19

Pharmaxis Investor Conference Call - Recording

A recording of the Pharmaxis Investor conference call held 18 December 2019 at 9.15am is available here.

18th Dec 19

Pharmaxis Business Plan Resourced to Complete Partnering and Clinical Development Milestones

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today provided an update on its business plan following a decision by Boehringer Ingelheim (BI) not to progress studies of the AOC3 inhibitor acquired from Pharmaxis in 2015 for the treatment of NASH.

A second study of the drug in diabetic retinopathy with associated milestone payments will continue with future development to be decided by BI following completion of the current phase 2a study due to report 2H 2020.

Pharmaxis closed the September quarter with $23 million cash, and in October received its 2019 R&D tax incentive of $6.2 million. In addition, Pharmaxis anticipates receipt of a US$10 million milestone payment for Bronchitol® from its US licensee Chiesi in Q3 2020 subject to FDA approval midyear.

The company’s drug development pipeline includes two drug projects that can be brought to significant valuation points with the current cash position:

Read full media release - pdf